AIRQ LICENSE AGREEMENT DOCUSIGN.PDF

Maricopa County — Formal (2026-11-18)

View PDF Item 45 Meeting page

Extracted text (via pymupdf_layout) 9797 characters
Docusign Docusign Envelope Envelope ID: ID: 2049C0DC-1391-80F6-8106-8B46A6BA9881 3F79677A-E5C6-8DB7-809C-7750F0DE0B45
License Agreement for the Asthma Impairment and Risk Questionnaire
(AIRQ®)
This License Agreement (the “Agreement”) is made effective as of the last date written below (the
“Effective Date”) by and between
(1) ASTRAZENECA PHARMACEUTICALS LP (“AstraZeneca”); and
(2) MARIICOPA COUNTY, a political subdivision of the State of Arizona, on behalf of the
Maricopa County Correctional Health Services (“MCCHS”) with an address of 3250 W Lower
Buckeye Rd, Phoenix, AZ 85009 (“Licensee”).
Parties
AstraZeneca and its affiliates (“we”, “us”, or “our”) own the Asthma Impairment and Risk
Questionnaire (AIRQ®).
RWS Life Sciences (“RWS”) is the license administrator of AIRQ® on behalf of us.
MCCHS is a health care professional, health care organization, or academic researcher, entirely
unaffiliated with a pharmaceutical company, who is interested in administering and using AIRQ®
either:
• in the clinical treatment of patients;
• as part of an independent clinical study, not sponsored by a pharmaceutical company (other
than us);
• or, both of the above.
Agreement
1 License
1.1 We grant you, as Licensee, a free, worldwide, non-exclusive, non-assignable, non-
sublicensable, revocable license for MCCHS to use AIRQ® and any Supporting
Materials under the following terms:
a. Upon execution of this Agreement, RWS will provide MCCHS with:
i. One digital copy (PDF) of the current version of the AIRQ®, in both U.S.
English and U.S. Spanish;
ii. One digital copy (PDF) of the current version of the Follow-up AIRQ® in
both U.S. English and U.S. Spanish; and
iii. Other implementation aids that may be necessary or helpful (“Supporting
Materials”).
b. You agree that MCCHS shall use AIRQ® exactly as worded, with wording in the
same order as provided to MCCHS (except for minor formatting changes relating
to implementation in digital formats), in the languages in which it has been made
available to MCCHS by us.
i. If MCCHS requires AIRQ® in a language that is not currently offered,
please have MCCHS contact RWS with that request. A translation fee
payable to RWS may apply.
ii. If MCCHS requires AIRQ® to be implemented in a digital format in its
1(5)

Docusign Docusign Envelope Envelope ID: ID: 2049C0DC-1391-80F6-8106-8B46A6BA9881 3F79677A-E5C6-8DB7-809C-7750F0DE0B45
electronic health records platform, please have MCCHS consult the
following guides, which provide instructions for implementing a compliant
version of AIRQ® on a digital platform:
1. Implementing AIRQ® in the Epic system
2. Implementing AIRQ® in the Cerner system
3. Implementing AIRQ® on another digital platform
c. MCCHS may only use, disclose, display, reproduce, or distribute AIRQ®
for the following purposes:
i. in the clinical treatment of patients;
ii. as part of an independent clinical study (not sponsored by another
pharmaceutical company);
iii. in the publication of its data from its independent clinical study, though it
must ensure we are credited as the owner of AIRQ® in its publications; and
iv. in discussion about AIRQ® with other members of the medical community
(for example, MCCHS may share blank copies of AIRQ® with colleagues as
part of those discussions).
d. You agree that MCCHS shall not use AIRQ® for any purpose other than stated above
and that all uses of AIRQ® by MCCHS shall be in compliance with applicable laws,
rules, and regulations. We reserve all rights not expressly granted to you.
e. MCCHS’s use of AIRQ® is subject to the terms of the Supporting Materials
and any separate terms of use for the AIRQ® software application (if used by
MCCHS).
2 Intellectual Property
2.1 Subject only to the license, as between you and us, AstraZeneca is the owner of (i) AIRQ®
and any Supporting Materials made available to MCCHS by us, and (ii) all modifications to,
adaptations of, improvements to, enhancements to, translations of or other changes to AIRQ®
created during the term of this Agreement (including by MCCHS for purposes of
implementation in digital formats) which shall be considered “Derivative Works” (as defined
under the copyright laws of the United States) of AIRQ®. All intellectual property rights,
including copyrights and all other rights in and to AIRQ® and any Supporting Materials,
shall be and remain at all times the exclusive property of AstraZeneca and its affiliates.
2.3 All data collected by MCCHS through its use of AIRQ® as permitted by this Agreement
shall be and remain at all times your exclusive property.
2.4 If MCCHS provides suggestions, ideas, feedback, or recommendations (“Feedback”) to us
relating to AIRQ® or the Supporting Materials, we are free to use, disclose, license,
reproduce, or otherwise exploit the Feedback as we see fit, without any credit or
remuneration to MCCHS.
3 Term and Termination
This Agreement shall be effective on the Effective Date and shall continue indefinitely,
provided that AstraZeneca and Licensee reserve the right to terminate this Agreement and
MCCHS’s use of AIRQ® if either party commits a material breach of its obligations under
2(5)

Docusign Docusign Envelope Envelope ID: ID: 2049C0DC-1391-80F6-8106-8B46A6BA9881 3F79677A-E5C6-8DB7-809C-7750F0DE0B45
this Agreement and fails to rectify such breach within thirty (30) days after having been
given a written request for such rectification.
3.1 The expiration or termination of this Agreement shall not affect any provision which is
expressly, or by implication, intended to continue to apply after expiration or termination,
including Section 2, this Section 3, Section 4, and Section 5 shall survive the termination of
this Agreement.
4 Disclaimer; Limitation of Liability
4.1 AIRQ® AND THE SUPPORTING MATERIALS ARE PROVIDED ON AN “AS-IS”
BASIS, AND MCCHS’S USE OR RELIANCE UPON THEM IS AT YOUR SOLE RISK
AND DISCRETION. ASTRAZENECA AND ITS AFFILIATES DISCLAIM ANY AND
ALL REPRESENTATIONS AND WARRANTIES REGARDING AIRQ® AND THE
SUPPORTING MATERIALS, WHETHER EXPRESS, IMPLIED, OR STATUTORY,
INCLUDING, WITHOUT LIMITATION, ALL IMPLIED OR STATUTORY
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, AND NON-INFRINGEMENT.
4.2 NEITHER US NOR OUR AFFILIATES SHALL BE LIABLE FOR ANY SPECIAL,
INDIRECT, INCIDENTAL, CONSEQUENTIAL (INCLUDING WITHOUT LIMITATION
LOST PROFITS) OR PUNITIVE DAMAGES IN RELATION TO THIS AGREEMENT,
MCCHS’S USE OF AIRQ® OR THE SUPPORTING MATERIALS, REGARDLESS OF
THE FORM AND BASIS OF THE ACTION AT ISSUE.
5 Miscellaneous
5.1 This Agreement, and any documents referenced herein, make up the entire agreement
between you and us, and supersede any prior agreements or communications. If either party
does not enforce a provision in this Agreement, it will not be considered a waiver.
5.2 The interpretation and construction of this Agreement shall be governed by the laws of the
State of Arizona. Any dispute related to this Agreement shall be resolved exclusively by
the state and federal courts of Arizona. This Agreement may be executed in multiple
counterparts, each of which is deemed an original, but all of which together shall constitute
one agreement. Signatures transmitted by facsimile or electronically via PDF attachment
shall be binding for all purposes as if they were original signatures.
5.3 This Agreement is subject to cancellation pursuant to A.R.S. §38-511 and subject to
Arizona Executive Order 2009-09, which executive order is incorporated herein by
reference as if set forth in full herein.
5.4 FORCED LABOR
a. By submitting a bid for this solicitation and/or entering into a contract as a result of this
solicitation, the contractor agrees to comply with all applicable portions of Arizona Revised
Statutes Section 35-394. Contracting; procurement; prohibition; written certification;
remedy; termination; exception; definitions.
b. Contractor certifies that it does not currently, and agrees to the duration of the contract,
that it will not use:
i. The forced labor of ethnic Uyghurs in the People’s Republic of China.
3(5)

Docusign Docusign Envelope Envelope ID: ID: 2049C0DC-1391-80F6-8106-8B46A6BA9881 3F79677A-E5C6-8DB7-809C-7750F0DE0B45
ii. Any goods or services produced by the forced labor of ethnic Uyghurs in the
People’s Republic of China.
iii. Any contractors, subcontractors, or suppliers that use the forced labor or any goods
or services produced by the forced labor of ethnic Uyghurs in the People’s Republic
of China.
c. If the contractor becomes aware during the term of the agreement that the contractor is not
in compliance with this paragraph, the contractor shall notify the County within five
business days after becoming aware of the noncompliance. If the contractor fails to provide
a written certification to the County that the contractor has remedied the noncompliance
within 180 days after notifying the County of its noncompliance, then the agreement
terminates, except that if the agreement termination date occurs before the end of the 180-
day period, the agreement terminates on the agreement termination date.
* Remainder of Page Intentionally Left Blank *
4(5)

Docusign Docusign Envelope Envelope ID: ID: 2049C0DC-1391-80F6-8106-8B46A6BA9881 3F79677A-E5C6-8DB7-809C-7750F0DE0B45
IN WITNESS WHEREOF, the parties have executed this Agreement as of the respective dates written
below.
RWS LIFE SCIENCES ON BEHALF OF
ASTRAZENECA, LP MARICOPA COUNTY
Authorized Individual: BOARD OF SUPERVISORS
By: By:
Name: ________________________ Nichole Lykes Name:
Title: _________________________ Lead LV Licensing Consultant Title: Chair, Board of Supervisors
Date: 10/9/2026 Date:
ATTEST:
By:
Name: ______________________________
Title: Clerk of the Board
Date:
APPROVED AS TO FORM:
By:
Name: Nikolaus G. Decker
Title: Deputy County Attorney
Date: 10/19/2026
5(5)